Compare ALVO & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALVO | AVLN |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Luxembourg | United States |
| Employees | 1460 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2026 |
| Metric | ALVO | AVLN |
|---|---|---|
| Price | $3.46 | $28.98 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 590.5K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $27.42 |
| 52 Week High | $9.94 | $33.32 |
| Indicator | ALVO | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 30.27 |
| Support Level | $3.09 | $27.42 |
| Resistance Level | $3.83 | $33.32 |
| Average True Range (ATR) | 0.23 | 2.86 |
| MACD | -0.05 | -0.35 |
| Stochastic Oscillator | 5.06 | 7.11 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.